HomeCompareHTCMY vs ABBV

HTCMY vs ABBV: Dividend Comparison 2026

HTCMY yields 3.84% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HTCMY wins by $31.2K in total portfolio value· pulled ahead in Year 8
10 years
HTCMY
HTCMY
● Live price
3.84%
Share price
$64.80
Annual div
$2.49
5Y div CAGR
39.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.6K
Annual income
$47,786.76
Full HTCMY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HTCMY vs ABBV

📍 HTCMY pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTCMYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTCMY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTCMY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTCMY
Annual income on $10K today (after 15% tax)
$326.62/yr
After 10yr DRIP, annual income (after tax)
$40,618.75/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HTCMY beats the other by $19,562.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTCMY + ABBV for your $10,000?

HTCMY: 50%ABBV: 50%
100% ABBV50/50100% HTCMY
Portfolio after 10yr
$118.0K
Annual income
$36,279.26/yr
Blended yield
30.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HTCMY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTCMY buys
0
ABBV buys
0
No recent congressional trades found for HTCMY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTCMYABBV
Forward yield3.84%3.06%
Annual dividend / share$2.49$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.8%40.6%
Portfolio after 10y$133.6K$102.3K
Annual income after 10y$47,786.76$24,771.77
Total dividends collected$103.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: HTCMY vs ABBV ($10,000, DRIP)

YearHTCMY PortfolioHTCMY Income/yrABBV PortfolioABBV Income/yrGap
1$11,237$537.19$11,550$430.00$313.00ABBV
2$12,812$788.70$13,472$627.96$660.00ABBV
3$14,884$1,174.93$15,906$926.08$1.0KABBV
4$17,710$1,783.32$19,071$1,382.55$1.4KABBV
5$21,721$2,772.25$23,302$2,095.81$1.6KABBV
6$27,685$4,442.60$29,150$3,237.93$1.5KABBV
7$37,020$7,397.91$37,536$5,121.41$516.00ABBV
8← crossover$52,537$12,925.17$50,079$8,338.38+$2.5KHTCMY
9$80,180$23,965.35$69,753$14,065.80+$10.4KHTCMY
10$133,579$47,786.76$102,337$24,771.77+$31.2KHTCMY

HTCMY vs ABBV: Complete Analysis 2026

HTCMYStock

Hitachi Construction Machinery Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, rental, and service of construction and transportation machinery, and other machines and devices worldwide. It offers mini excavators and wheel loaders, road construction machinery, wheel loaders, large and ultra-large hydraulic excavators, rigid dump trucks, and double arm working machines. The company also provides ICT construction solutions; ConSite that monitors machines' operational status, alarms by sending monthly operational reports, and notifies emergency alarms; Fleet management system, which offers real-time monitoring of each dump truck to optimize vehicle operation; and autonomous haulage system that enables the unmanned, autonomous operation of mining dump trucks. In addition, it provides parts, including hydraulic oil and filters, high pressure hoses, ground engaging tools, and remanufacturing components; and used equipment. The company was incorporated in 1951 and is headquartered in Tokyo, Japan. Hitachi Construction Machinery Co., Ltd. is a subsidiary of Hitachi, Ltd.

Full HTCMY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HTCMY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTCMY vs SCHDHTCMY vs JEPIHTCMY vs OHTCMY vs KOHTCMY vs MAINHTCMY vs JNJHTCMY vs MRKHTCMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.